Comprehensive scientific comparison between Retatrutide (GLP-1/GIP/Glucagon) and Tirzepatide (GLP-1/GIP). Mechanism, weight loss efficacy, liver fat clearance, and dosage.
Retatrutide demonstrates superior peak weight loss (up to 24.2% in Phase 2) and accelerated liver fat clearance due to its glucagon receptor activation, whereas Tirzepatide is already FDA-approved (Mounjaro/Zepbound) with an established safety profile and lower resting heart rate elevation.
| Evaluation Feature | Retatrutide | Tirzepatide | Analytical Winner / Takeaway |
|---|---|---|---|
| Target Receptors | GLP-1 + GIP + Glucagon (Triple Agonist) | GLP-1 + GIP (Dual Agonist) | Retatrutide adds direct glucagon thermogenesis |
| Average Weight Loss (Trials) | Up to 24.2% at 48 weeks | 15.0% - 22.5% at 72 weeks | Retatrutide (faster rate of loss) |
| Liver Fat Clearance | >80% relative reduction in hepatic fat | ~40-50% reduction in hepatic fat | Retatrutide excels in hepatic steatosis |
| Regulatory Status | Phase 3 Clinical Trials (Triumph trials) | FDA Approved (Mounjaro / Zepbound) | Tirzepatide has full commercial approval |
Tirzepatide is a dual agonist targeting GLP-1 and GIP receptors to slow gastric emptying, suppress appetite, and improve insulin sensitivity. Retatrutide introduces a third target: the Glucagon receptor, which elevates energy expenditure, thermogenesis, and hepatic lipid oxidation directly in the liver.
Both peptides have approximate 5-6 day half-lives and are administered once weekly via subcutaneous injection.
Tirzepatide follows a standard monthly escalation (2.5mg up to 15mg weekly). Retatrutide research protocols generally start at 1-2mg weekly and titrate up to 8-12mg weekly.
Both are potent single-agent therapies. However, Retatrutide provides superior metabolic rate elevation, whereas Tirzepatide may produce slightly fewer autonomic heart rate fluctuations during titration.
If FDA approval and proven long-term clinical safety data are paramount, Tirzepatide is the benchmark. For cutting-edge maximum fat loss and reversing severe hepatic steatosis (NAFLD/MASH), Retatrutide represents the next evolution.